At the initiative of Dr Martin Bangemann, Member of the Commission with responsibility for industrial policy, and the pharmaceuti- cal sector in particular, a second hearing was held at the EMEA on 21 October 1996 to review the new European marketing authorisation system with representatives of various interest groups.